193 related articles for article (PubMed ID: 28731238)
1. A critical eye on registry data in psoriasis.
Egeberg A; Nast A
Br J Dermatol; 2017 Jul; 177(1):245-246. PubMed ID: 28731238
[No Abstract] [Full Text] [Related]
2. Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Shear NH; Alhusayen R; Fernandez-Obregon A; Kimball AB; Menter A; Wu JJ; Goyal K; Patel H; Lin R; Armstrong AW
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e544-e547. PubMed ID: 28622413
[No Abstract] [Full Text] [Related]
3. Biologics for psoriasis: more drugs, new patient categories, but fresh challenges for clinical dermatologists.
Pink AE; Smith CH
Br J Dermatol; 2017 Jul; 177(1):7-8. PubMed ID: 28731243
[No Abstract] [Full Text] [Related]
4. Why Biologic Therapies Sometimes Lose Efficacy.
Strober BE
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S78-80. PubMed ID: 27525443
[TBL] [Abstract][Full Text] [Related]
5. Proposal for long-term protocols after Psoriasis Area and Severity Index clear with initial biologic therapy: Happily ever after with or without biologics in psoriasis therapy.
Sano S
J Dermatol; 2017 Oct; 44(10):e234-e235. PubMed ID: 28623843
[No Abstract] [Full Text] [Related]
6. Geographic Variations in Biologic Therapy and Disease Characteristics: A Pilot-Study in the Corrona Psoriasis Registry.
Enos CW; O'Connell KA; Harrison RW; McLean RR; Dude B; Van Voorhees AS
J Drugs Dermatol; 2020 Nov; 19(11):1119-1122. PubMed ID: 33196741
[No Abstract] [Full Text] [Related]
7. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Menter A; Papp KA; Gooderham M; Pariser DM; Augustin M; Kerdel FA; Fakharzadeh S; Goyal K; Calabro S; Langholff W; Chavers S; Naessens D; Sermon J; Krueger GG
J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1148-58. PubMed ID: 27027388
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries.
Kojanova M; Fialova J; Cetkovska P; Gkalpakiotis S; Jircikova J; Dolezal T; Arenberger P;
Int J Dermatol; 2017 Apr; 56(4):428-434. PubMed ID: 28181669
[TBL] [Abstract][Full Text] [Related]
9. The role of biologics and other systemic agents in the treatment of pediatric psoriasis.
Wright NA; Piggott CD; Eichenfield LF
Semin Cutan Med Surg; 2010 Mar; 29(1):20-7. PubMed ID: 20430304
[No Abstract] [Full Text] [Related]
10. Combining biologics with methotrexate in psoriasis: a systematic review.
van Bezooijen JS; Prens EP; Pradeepti MS; Atiqi R; Schreurs MWJ; Koch BCP; van Gelder T; van Doorn MBA
Br J Dermatol; 2015 Jun; 172(6):1676-1680. PubMed ID: 25470815
[No Abstract] [Full Text] [Related]
11. Efficacies of biological therapies at week 12 in patients with plaque psoriasis in real-world academic clinical practice: a Canadian multicentre retrospective study.
Shahbaz A; Qiang J; Marinas JEC; Kim WB; Greaves S; Yeung J
Br J Dermatol; 2017 Jul; 177(1):297-298. PubMed ID: 27639251
[No Abstract] [Full Text] [Related]
12. Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity?
van de Kerkhof PC; Mrowietz U; Segaert S; Kragballe K
Br J Dermatol; 2007 Apr; 156(4):771-2. PubMed ID: 17263798
[No Abstract] [Full Text] [Related]
13. Biologicals in the treatment of psoriasis.
Boker A; Kimball AB; Rolz-Cruz G
Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
[TBL] [Abstract][Full Text] [Related]
14. Non-tuberculous mycobacterial infections in psoriasis patients treated with biologics.
Choi YM; Adelzadeh L; Wu JJ
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e99-e101. PubMed ID: 26388307
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N
Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307
[TBL] [Abstract][Full Text] [Related]
16. New drugs and treatment targets in psoriasis.
Kofoed K; Skov L; Zachariae C
Acta Derm Venereol; 2015 Feb; 95(2):133-9. PubMed ID: 25111317
[TBL] [Abstract][Full Text] [Related]
17. Inequalities in access to biological treatments for psoriasis: results from the Italian Psocare registry.
Naldi L; Cazzaniga S; Di Mercurio M; Grossi E; Addis A;
Br J Dermatol; 2017 May; 176(5):1331-1338. PubMed ID: 27973689
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
Blauvelt A; Reich K; Warren RB; Szepietowski JC; Sigurgeirsson B; Tyring SK; Messina I; Bhosekar V; Oliver J; Papavassilis C; Frueh J; Langley RGB
Br J Dermatol; 2017 Sep; 177(3):879-881. PubMed ID: 28498514
[No Abstract] [Full Text] [Related]
19. Psoriasis therapy in real life: the need for registries.
Schmitt-Egenolf M
Dermatology; 2006; 213(4):327-30. PubMed ID: 17135739
[TBL] [Abstract][Full Text] [Related]
20. Advanced Therapy Treatment for Psoriasis: A Single-Site Retrospective Study of Prescribing Outcomes.
Kim C; Joerg L; Levitt J
Skinmed; 2017; 15(6):493-495. PubMed ID: 29282198
[No Abstract] [Full Text] [Related]
[Next] [New Search]
